| Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results CG Goetz, BC Tilley, SR Shaftman, GT Stebbins, S Fahn, ... Movement disorders: official journal of the Movement Disorder Society 23 (15 …, 2008 | 7151 | 2008 |
| Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 ER Dorsey, R Constantinescu, JP Thompson, KM Biglan, RG Holloway, ... Neurology 68 (5), 384-386, 2007 | 3427 | 2007 |
| Levodopa and the progression of Parkinson's disease Parkinson Study Group New England Journal of Medicine 351 (24), 2498-2508, 2004 | 2377 | 2004 |
| Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients D Weintraub, J Koester, MN Potenza, AD Siderowf, M Stacy, V Voon, ... Archives of neurology 67 (5), 589-595, 2010 | 1776 | 2010 |
| The Parkinson progression marker initiative (PPMI) K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ... Progress in neurobiology 95 (4), 629-635, 2011 | 1724 | 2011 |
| Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease S Hoops, S Nazem, AD Siderowf, JE Duda, SX Xie, MB Stern, ... Neurology 73 (21), 1738-1745, 2009 | 1450 | 2009 |
| Association of dopamine agonist use with impulse control disorders in Parkinson disease D Weintraub, AD Siderowf, MN Potenza, J Goveas, KH Morales, JE Duda, ... Archives of neurology 63 (7), 969-973, 2006 | 874 | 2006 |
| A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Parkinson Study Group Archives of Neurology 59 (12), 1937-1943, 2002 | 704 | 2002 |
| Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology D Cella, JS Lai, CJ Nowinski, D Victorson, A Peterman, D Miller, ... Neurology 78 (23), 1860-1867, 2012 | 678 | 2012 |
| Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated JL Robinson, EB Lee, SX Xie, L Rennert, ER Suh, C Bredenberg, ... Brain 141 (7), 2181-2193, 2018 | 623 | 2018 |
| Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease D Weintraub, S Hoops, JA Shea, KE Lyons, R Pahwa, ... Movement disorders: official journal of the Movement Disorder Society 24 (10 …, 2009 | 595 | 2009 |
| Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases H Nakashima-Yasuda, K Uryu, J Robinson, SX Xie, H Hurtig, JE Duda, ... Acta neuropathologica 114, 221-229, 2007 | 492 | 2007 |
| The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ... Annals of clinical and translational neurology 5 (12), 1460-1477, 2018 | 484 | 2018 |
| Impulse control disorders in Parkinson disease: a multicenter case–control study V Voon, M Sohr, AE Lang, MN Potenza, AD Siderowf, J Whetteckey, ... Annals of neurology 69 (6), 986-996, 2011 | 483 | 2011 |
| Montreal cognitive assessment performance in patients with Parkinson's disease with “normal” global cognition according to mini‐mental state examination score S Nazem, AD Siderowf, JE Duda, T Ten Have, A Colcher, SS Horn, ... Journal of the American Geriatrics Society 57 (2), 304-308, 2009 | 474 | 2009 |
| Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson … JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ... JAMA neurology 70 (10), 2013 | 455 | 2013 |
| CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease A Siderowf, SX Xie, H Hurtig, D Weintraub, J Duda, A Chen-Plotkin, ... Neurology 75 (12), 1055-1061, 2010 | 412 | 2010 |
| Questionnaire for impulsive‐compulsive disorders in Parkinson's Disease–Rating Scale D Weintraub, E Mamikonyan, K Papay, JA Shea, SX Xie, A Siderowf Movement disorders 27 (2), 242-247, 2012 | 399 | 2012 |
| Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study A Siderowf, L Concha-Marambio, DE Lafontant, CM Farris, Y Ma, ... The Lancet Neurology 22 (5), 407-417, 2023 | 375 | 2023 |
| Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition MJ Pontecorvo, MD Devous Sr, M Navitsky, M Lu, S Salloway, FW Schaerf, ... Brain 140 (3), 748-763, 2017 | 367 | 2017 |